| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 01/20/2005 | CA2531636A1 Compositions for activating the infiltration activity of dendritic cells and immunopotentiating agents |
| 01/20/2005 | CA2531629A1 Medicinal composition containing nf-.kappa.b decoy for treating and preventing respiratory diseases and method of using the same |
| 01/20/2005 | CA2531512A1 Organosilicon compounds and their use |
| 01/20/2005 | CA2531511A1 Silicon compounds and their use |
| 01/20/2005 | CA2531485A1 Malonamide derivatives |
| 01/20/2005 | CA2531417A1 Herbal compositions for the treatment and prevention of prostate disorders |
| 01/20/2005 | CA2531283A1 Specific human antibodies |
| 01/20/2005 | CA2531235A1 Applications of a new class of enzymes: sulfiredoxines. |
| 01/20/2005 | CA2530314A1 Appl proteins as rab5 effectors |
| 01/20/2005 | CA2529323A1 Tetracyclic compounds as c-met inhibitors |
| 01/20/2005 | CA2528669A1 Compositions and methods for treating and diagnosing cancer |
| 01/19/2005 | EP1498491A1 METHOD OF ENHANCING ACTIVITY OF ANTIBODY COMPOSITION OF BINDING TO Fc GAMMA RECEPTOR IIIa |
| 01/19/2005 | EP1498490A1 Process for producing antibody composition |
| 01/19/2005 | EP1498485A1 Cells with modified genome |
| 01/19/2005 | EP1498479A2 Non-myeloablative tolerogenic treatment |
| 01/19/2005 | EP1498427A1 Immunoglobulins devoid of light chains |
| 01/19/2005 | EP1498420A1 Phospholipid derivative |
| 01/19/2005 | EP1498406A1 Novel hydronaphthalene compounds, prepared by a rhodium catalysed ring opening reaction in the presence of phosphine ligand |
| 01/19/2005 | EP1498137A1 Remedy for lung cancer |
| 01/19/2005 | EP1498136A2 Non-myeloablative tolerogenic treatment |
| 01/19/2005 | EP1498129A1 Use of adenoviruses mutated in the va genes for cancer treatment |
| 01/19/2005 | EP1498127A1 Use of antitumor indolopyrrolocarbazole derivative and other anticancer agent in combination |
| 01/19/2005 | EP1498125A1 Use of compounds having ccr antagonism |
| 01/19/2005 | EP1498121A1 Use of specific cyclolignans |
| 01/19/2005 | EP1497659A2 An ephrin-b receptor protein involved in carcinoma |
| 01/19/2005 | EP1497658A2 Protein involved in cancer |
| 01/19/2005 | EP1497656A2 Diagnosis of carcinoma using raig1 polypeptides |
| 01/19/2005 | EP1497470A2 Methods of identifying compounds that modulate a dna repair pathway and/or retroviral infectivity, the compounds, and uses thereof |
| 01/19/2005 | EP1497467A2 Oligonucleotides from sequences coding for the surface component of ptlv envelope proteins and uses thereof |
| 01/19/2005 | EP1497466A2 Binary or polynary targeting and uses thereof |
| 01/19/2005 | EP1497462A2 Genomic screen for epigenetically silenced genes associated with cancer |
| 01/19/2005 | EP1497438A1 Means and methods for the production of adenovirus vectors |
| 01/19/2005 | EP1497417A2 Epha2 antigen t epitopes |
| 01/19/2005 | EP1497412A2 Adenovirus vectors for immunotherapy |
| 01/19/2005 | EP1497315A2 Nucleic acid-associated proteins |
| 01/19/2005 | EP1497309A2 Aminoalkyl sterol compounds having an anti-tumoral and neuroprotective activity |
| 01/19/2005 | EP1497296A1 1,4 DIAZOCINO 7,8,1-hi INDOLE DERIVATIVES AS ANTIPSYCHOTIC AND ANTIOBESITY AGENTS |
| 01/19/2005 | EP1497295A1 Farnesyl transferase inhibiting tricyclic quinazoline derivatives substituted with carbon-linked imidazoles or triazoles |
| 01/19/2005 | EP1497294A1 1,2,3,4,7,8-HEXAHYDRO-6 i H /i - 1,4 DIAZEPINO 6,7 ,1- i 1J /i QUINOLINE DERIVATIVES AS ANTIPSYCHOTIC AND ANTI OBESITY AGENTS |
| 01/19/2005 | EP1497287A1 Quinolinone derivatives |
| 01/19/2005 | EP1497274A2 Terphenyl derivatives, preparation thereof, compositions containing same |
| 01/19/2005 | EP1497273A2 Hydroxamic acid derivatives |
| 01/19/2005 | EP1497268A2 Nitric oxide donors, compositions and methods of use |
| 01/19/2005 | EP1497247A2 Mimics of acyl coenzyme-a, compositions thereof, and methods of cholesterol management and related uses |
| 01/19/2005 | EP1496979A2 Protamine-adenoviral vector complexes and methods of use |
| 01/19/2005 | EP1496941A1 Glycodendrimers having biological activity |
| 01/19/2005 | EP1496940A2 Methods of treating diabetes using pde 11a inhibitors |
| 01/19/2005 | EP1496939A2 Modified cea nucleic acid and expression vectors |
| 01/19/2005 | EP1496937A2 Dna vaccine combined with an inducer of tumor cell apoptosis |
| 01/19/2005 | EP1496934A2 Adjuvant enhanced immunotherapy |
| 01/19/2005 | EP1496933A2 Use of interleukin-19 to treat ovarian cancer |
| 01/19/2005 | EP1496925A2 Use of interleukin-24 to treat ovarian cancer |
| 01/19/2005 | EP1496923A1 Cancer immunotherapy |
| 01/19/2005 | EP1496918A1 Pharmaceutical composition comprising arsenite for the treatment of malignancy |
| 01/19/2005 | EP1496917A1 Combination of a beta-2 adrenoceptor agonists and an aminosugars and their use for the treatment immunomodulatory disorders |
| 01/19/2005 | EP1496914A1 (20S)-1a-HYDROXY-2a-METHYL AND 2&bgr;-METHYL-19-NOR-VITAM IN D sb 3 /sb AND THEIR USES |
| 01/19/2005 | EP1496910A1 Kinase inhibitors |
| 01/19/2005 | EP1496909A1 Combination therapy for the treatment of cancer |
| 01/19/2005 | EP1496908A1 Combination of glivec(sti571) with a cyclin-dependent kinase inhibitor, especially flavopiridol in the treatment of cancer |
| 01/19/2005 | EP1496907A2 Tyrosine kinase inhibitors |
| 01/19/2005 | EP1496906A1 Inhibitors of akt activity |
| 01/19/2005 | EP1496905A2 Modulators of hedgehog signaling pathways, compositions and uses related thereto |
| 01/19/2005 | EP1496903A1 Anhydrovinblastine for the treatment of cancer |
| 01/19/2005 | EP1496898A2 Tyrosine kinase inhibitors |
| 01/19/2005 | EP1496897A1 Tyrosine kinase inhibitors |
| 01/19/2005 | EP1496896A1 Inhibitors of akt activity |
| 01/19/2005 | EP1496895A1 Use of cyclopamine in the treatment of psoriasis and other skin disorders |
| 01/19/2005 | EP1496894A1 Angiogenesis inhibitors |
| 01/19/2005 | EP1496892A2 1h-benzo(f)indazol-5-yl derivatives as selective glucocorticoid receptor modulators |
| 01/19/2005 | EP1496888A1 Non-toxix amounts of protein-aggregating substances stimulate hsp70 expression and function as anti-tumor agents |
| 01/19/2005 | EP1496880A2 SYNERGISTIC EFFECTS OF NUCLEAR TRANSCRIPTION FACTOR NF-kB INHIBITORS AND ANTI-NEOPLASTIC AGENTS |
| 01/19/2005 | EP1496878A1 Methods for identification of modulators of angiogenesis, compounds discovered thereby, and methods of treatment using the compounds |
| 01/19/2005 | EP1496865A1 Method for the production of crystals, crystals obtained by said method, and use thereof in pharmaceutical formulations |
| 01/19/2005 | EP1496863A2 Preparation and use of a stable formulation of allosteric effector compounds |
| 01/19/2005 | EP1496743A2 Compositions and methods for the therapy and diagnosis of lung cancer |
| 01/19/2005 | EP1412332B1 Quinoline derivatives and use thereof as antitumor agents |
| 01/19/2005 | EP1392366A4 Nuclear receptor-mediated introduction of a pna into cell nuclei |
| 01/19/2005 | EP1362053A4 Terminally-branched polymeric linkers and polymeric conjugates containing the same |
| 01/19/2005 | EP1347958B1 Process for preparing distamycin derivatives |
| 01/19/2005 | EP1313738A4 Process for the preparation and purification of thiol-containing maytansinoids |
| 01/19/2005 | EP1272199B1 Combination therapies with vascular damaging activity |
| 01/19/2005 | EP1230244B1 Pyrazolecarboxylic acid tricyclic derivatives, preparation and pharmaceutical compositions containing same |
| 01/19/2005 | EP1208104B1 Tricyclic inhibitors of poly(adp-ribose) polymerases |
| 01/19/2005 | EP1165493B1 Nitrogen mustard compounds and prodrugs therefor |
| 01/19/2005 | EP1124562B1 Combination therapy to treat hepatitis b virus |
| 01/19/2005 | EP1100589B1 Use of propionyl l-carnitine and acetyl l-carnitine in the preparation of medicaments with anticancer activity |
| 01/19/2005 | EP1027365B1 Antitumour uridine analogues |
| 01/19/2005 | EP0789588B1 Method for making a medicament for treating secondary immunodeficiency |
| 01/19/2005 | CN1568426A Novel method of assaying immune activity |
| 01/19/2005 | CN1568373A RNA interference mediating small rna molecules |
| 01/19/2005 | CN1568369A Hybrid interferon/interferon Tau proteins, compositions and methods of use |
| 01/19/2005 | CN1568331A Biological products |
| 01/19/2005 | CN1568324A 1-glyoxylamide indolizines for treating cancer |
| 01/19/2005 | CN1568323A Activator for peroxisome proliferator-activated receptor delta |
| 01/19/2005 | CN1568322A Pharmaceutically active sulfonamide derivatives bearing both lipophilic and ionisable moieties as inhibitors of protein junkinases |
| 01/19/2005 | CN1568320A 异羟肟酸衍生物 Hydroxamic acid derivatives |
| 01/19/2005 | CN1568316A Activator for peroxisome proliferator-responsive receptor delta |
| 01/19/2005 | CN1568310A Heterocyclic inhibitors of glycogen synthase kinase GSK-3 |
| 01/19/2005 | CN1568309A 4'-methanesulfonyl-biphenyl derivatives as a highly selective cyclooxygenase-2 inhibitor |
| 01/19/2005 | CN1568308A Salts of guanidine derivatives and pharmaceutical preparations consisting thereof |